


Financial Tear Sheet

Corporate Profile

Who is Organovo?

- We participate in attractive and growing markets with critical unmet needs
- We benefit from favorable competitive dynamics and a first mover advantage
- We're a technology leader with a strong IP portfolio
- We're leveraging our technology platform to build a robust product and service platform across the high-value drug profiling and therapeutic tissues markets

 2017 Annual Report

 Investor Fact Sheet

 Investor Presentation

Primary IR Contact

Steve E. Kunszabo
 VP, Investor Relations & Corporate Communications
Phone: 858-224-1092
Email: skunszabo@organovo.com

Stock Information

ONVO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$1.99
Change (%)	▲ 0.02 (1.02%)
Volume	778,708
52 Week Low	\$1.75
Market Cap	\$208,086,258
Rolling EPS	-0.39
PE Ratio	0
Shares Outstanding	105,627,542
Data as of 09/25/17 4:00 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent Press Releases & Upcoming Events

08/23/17

Organovo Sponsors Pioneering Research With Amgen and Medikine in Critical Areas of Liver and Kidney Disease

08/09/17

Organovo Announces Fiscal First-Quarter 2018 Results; Company Affirms Full-Year Fiscal 2018 Outlook

07/31/17

Organovo and UC San Diego Receive \$1.7 Million Grant From National Institutes of Health to Study Liver Disease

There are currently no events scheduled.

SEC Filings

Filing Date	Form
08/28/17	4
08/28/17	4
08/28/17	4
08/28/17	4

Corporate Governance

Taylor J. Crouch	President & Chief Executive Officer
Sharon Collins Presnell, Ph.D.	Chief Scientific Officer, Organovo & President, Samsara
Eric Michael David, M.D., J.D.	Chief Strategy Officer and Executive Vice President of Preclinical Development
Jennifer Kinsbruner Bush, J.D.	General Counsel, Corporate Secretary and Compliance Officer
Susan Daugherty	Senior Vice President, Human Resources
Paul Gallant	General Manager